{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:18Z","timestamp":1793398218798,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81200607"],"award-info":[{"award-number":["81200607"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["2017B11"],"award-info":[{"award-number":["2017B11"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-022-06700-3","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T06:10:56Z","timestamp":1657692656000},"page":"1711-1721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT"],"prefix":"10.1007","volume":"306","author":[{"given":"Renyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-8694","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"6700_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6309","author":"N Roos","year":"2011","unstructured":"Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O (2011) Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. https:\/\/doi.org\/10.1136\/bmj.d6309","journal-title":"BMJ"},{"key":"6700_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejogrb.2007.12.018","volume":"139","author":"X Chen","year":"2008","unstructured":"Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y (2008) Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol 139:59\u201364. https:\/\/doi.org\/10.1016\/j.ejogrb.2007.12.018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"6700_CR3","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/humrep\/det262","volume":"28","author":"Li Rong","year":"2013","unstructured":"Rong Li, Qiu Z, Dongzi Y, Li S, Shulan Lu, Xiaoke Wu et al (2013) Prevalence of polycystic ovary syndrome in women in China: a large communitybased study. Hum Reprod 28:2562\u20132569. https:\/\/doi.org\/10.1093\/humrep\/det262","journal-title":"Hum Reprod"},{"key":"6700_CR4","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/humrep\/des232","volume":"27","author":"BO Yildiz","year":"2012","unstructured":"Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H (2012) Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27:3067\u20133073. https:\/\/doi.org\/10.1093\/humrep\/des232","journal-title":"Hum Reprod"},{"key":"6700_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/obr.12829","volume":"20","author":"MB Khomami","year":"2019","unstructured":"Khomami MB, Joham AE, Boyle JA, Piltonen T, Silagy M, Chavy A et al (2019) Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity\u2014a systematic review, meta-analysis, and meta-regression. Obes Rev 20:659\u2013674. https:\/\/doi.org\/10.1111\/obr.12829","journal-title":"Obes Rev"},{"key":"6700_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.fertnstert.2017.06.026","volume":"108","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2017","unstructured":"Practice Committee of the American Society for Reproductive Medicine (2017) Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril 108:426\u2013441. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.06.026","journal-title":"Fertil Steril"},{"key":"6700_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck DJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647\u2013654. https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7","journal-title":"Metabolism"},{"key":"6700_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.fertnstert.2011.11.036","volume":"97","author":"JC Marshall","year":"2012","unstructured":"Marshall JC, Dunaif A (2012) Should all women with PCOS be treated for insulin resistance? Fertil Steril 97:18\u201322. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.11.036","journal-title":"Fertil Steril"},{"key":"6700_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00404-017-4480-z","volume":"4","author":"Y Xu","year":"2017","unstructured":"Xu Y, Wu Y, Huang Q (2017) Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. Arch Gynecol Obstet 4:661\u2013677. https:\/\/doi.org\/10.1007\/s00404-017-4480-z","journal-title":"Arch Gynecol Obstet"},{"key":"6700_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cen.13795","volume":"3","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol 3:251\u2013268. https:\/\/doi.org\/10.1111\/cen.13795","journal-title":"Clin Endocrinol"},{"key":"6700_CR11","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1093\/humrep\/17.11.2858","volume":"17","author":"CJ Glueck","year":"2002","unstructured":"Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L (2002) Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17:2858\u20132864. https:\/\/doi.org\/10.1093\/humrep\/17.11.2858","journal-title":"Hum Reprod"},{"key":"6700_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-8587(19)30002-6","volume":"7","author":"TS L\u00f8vvik","year":"2019","unstructured":"L\u00f8vvik TS, Carlsen SM, Salvesen \u00d8, Steffensen B, Bixo M, G\u00f3mez-Real F et al (2019) Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7:256\u2013266. https:\/\/doi.org\/10.1016\/S2213-8587(19)30002-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6700_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0175","volume":"179","author":"V Salamun","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E (2018) Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol 179:1\u201311. https:\/\/doi.org\/10.1530\/EJE-18-0175","journal-title":"Eur J Endocrinol"},{"key":"6700_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000446951","volume":"81","author":"Q Yang","year":"2016","unstructured":"Yang Q, Wang F (2016) Successful pregnancy after improving insulin resistance with the Glucagon-Like Peptide-1 analogue in a woman with polycystic ovary syndrome: a case report and review of the literature. Gynecol Obstet Invest 81:477\u2013480. https:\/\/doi.org\/10.1159\/000446951","journal-title":"Gynecol Obstet Invest"},{"key":"6700_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/524517","volume":"2014","author":"H Wu","year":"2014","unstructured":"Wu H, Sui C, Xu H, Xia F, Zhai H, Zhang H et al (2014) The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic- euglycemic clamp. J Diabetes Res 2014:1\u201310. https:\/\/doi.org\/10.1155\/2014\/524517","journal-title":"J Diabetes Res"},{"key":"6700_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng S, Lin R, Xie Y, Chen H et al (2017) Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol 87:767\u2013774. https:\/\/doi.org\/10.1111\/cen.13454","journal-title":"Clin Endocrinol"},{"key":"6700_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41\u201347. https:\/\/doi.org\/10.1016\/j.fertnstert.2003.10.004","journal-title":"Hum Reprod"},{"key":"6700_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/cd17-0119","volume":"36","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes 36:14\u201337. https:\/\/doi.org\/10.2337\/cd17-0119","journal-title":"Clin Diabetes"},{"key":"6700_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"6700_CR20","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/humrep\/dev024","volume":"30","author":"A Zeadna","year":"2015","unstructured":"Zeadna A, Son WY, Moon JH, Dahan MH (2015) A comparison of biochemical pregnancy rates between women who underwent IVF and fertile controls who conceived spontaneously. Hum Reprod 30:783\u2013788. https:\/\/doi.org\/10.1093\/humrep\/dev024","journal-title":"Hum Reprod"},{"key":"6700_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.diabres.2013.10.012","volume":"103","author":"G L\u00f3pez Stewart","year":"2014","unstructured":"L\u00f3pez Stewart G (2014) Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline. Diabetes Res Clin Pract 103:341\u201363. https:\/\/doi.org\/10.1016\/j.diabres.2013.10.012","journal-title":"Diabetes Res Clin Pract"},{"key":"6700_CR22","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1210\/jc.2013-2350","volume":"98","author":"RS Legro","year":"2013","unstructured":"Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad H, Pasquali R et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 98:4565\u20134592. https:\/\/doi.org\/10.1210\/jc.2013-2350","journal-title":"J Clin Endocrinol Metab"},{"key":"6700_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","volume":"21","author":"NF Goodman","year":"2015","unstructured":"Goodman NF, Cobin RH, Futterweit W (2015) American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome\u2013part 2. Endocr Pract 21:1415\u20131426. https:\/\/doi.org\/10.4158\/EP15748.DSCPT2","journal-title":"Endocr Pract"},{"key":"6700_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1210\/er.2002-0015","volume":"24","author":"V De Leo","year":"2003","unstructured":"De Leo V, la Marca A, Petraglia F (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633\u2013667. https:\/\/doi.org\/10.1210\/er.2002-0015","journal-title":"Endocr Rev"},{"key":"6700_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R (2008) Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:2670\u20132678. https:\/\/doi.org\/10.1210\/jc.2008-0115","journal-title":"J Clin Endocrinol Metab"},{"key":"6700_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","volume":"392","author":"Y Han","year":"2019","unstructured":"Han Y, Li Y, He B (2019) GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online 392:332\u2013342. https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.017","journal-title":"Reprod Biomed Online"},{"key":"6700_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/09513590.2014.975686","volume":"31","author":"B Artunc-Ulkumen","year":"2015","unstructured":"Artunc-Ulkumen B, Pala HG, Pala EE, Yavasoglu A, Yigitturk G, Erbas O (2015) Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats. Gynecol Endocrinol 31:196\u2013201. https:\/\/doi.org\/10.3109\/09513590.2014.975686","journal-title":"Gynecol Endocrinol"},{"key":"6700_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Frossing","year":"2018","unstructured":"Frossing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C et al (2018) Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab 20:215\u2013218. https:\/\/doi.org\/10.1111\/dom.13053","journal-title":"Diabetes Obes Metab"},{"key":"6700_CR29","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/obr.12720","volume":"19","author":"FF Wang","year":"2018","unstructured":"Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL, Qu F et al (2018) Pharmacologic therapy to induce weight loss in women who have obesity\/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev 19:1424\u20131445. https:\/\/doi.org\/10.1111\/obr.12720","journal-title":"Obes Rev"},{"issue":"3","key":"6700_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00404-020-05951-2","volume":"303","author":"S Abraham Gnanadass","year":"2021","unstructured":"Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A (2021) Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet 303(3):631\u2013643. https:\/\/doi.org\/10.1007\/s00404-020-05951-2","journal-title":"Arch Gynecol Obstet"},{"key":"6700_CR31","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1056\/NEJM200506303522620","volume":"352","author":"DA Ehrmann","year":"2005","unstructured":"Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223\u20131236. https:\/\/doi.org\/10.1056\/NEJM200506303522620","journal-title":"N Engl J Med"},{"key":"6700_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","volume":"24","author":"L Lynch","year":"2016","unstructured":"Lynch L, Hogan AE, Duquette D, Lester C, Banks A, LeClair K et al (2016) iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab 24:510\u2013519. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.003","journal-title":"Cell Metab"},{"key":"6700_CR33","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1097\/CM9.0000000000001712","volume":"23","author":"RL Ma","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ et al (2021) Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J 23:2882\u20132889. https:\/\/doi.org\/10.1097\/CM9.0000000000001712","journal-title":"Chin Med J"},{"key":"6700_CR34","doi-asserted-by":"publisher","first-page":"1000937","DOI":"10.1016\/j.molmet.2020.01.001","volume":"35","author":"MA Sanchez-Garrido","year":"2020","unstructured":"Sanchez-Garrido MA, Tena-Sempere M (2020) Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 35:1000937\u20131000952. https:\/\/doi.org\/10.1016\/j.molmet.2020.01.001","journal-title":"Mol Metab"},{"key":"6700_CR35","doi-asserted-by":"publisher","first-page":"30679","DOI":"10.1038\/srep30679","volume":"27","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Sun X, Sun X, Meng F, Hu M, Li X et al (2016) Molecular characterization of insulin resistance and glycolytic metabolism in the rat uterus. Sci Rep 27:30679. https:\/\/doi.org\/10.1038\/srep30679","journal-title":"Sci Rep"},{"key":"6700_CR36","doi-asserted-by":"publisher","first-page":"e1420","DOI":"10.1210\/clinem\/dgaa692","volume":"3","author":"T Tao","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J et al (2021) Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab 3:e1420\u2013e1432. https:\/\/doi.org\/10.1210\/clinem\/dgaa692","journal-title":"J Clin Endocrinol Metab"},{"key":"6700_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17512433.2017.1292125","volume":"10","author":"EM Lamos","year":"2017","unstructured":"Lamos EM, Malek R, Davis SN (2017) GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol 10:401\u2013408. https:\/\/doi.org\/10.1080\/17512433.2017.1292125","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6700_CR38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s0015-0282(03)01007-0","volume":"80","author":"XK Wu","year":"2003","unstructured":"Wu XK, Zhou SY, Liu JX, P\u00f6ll\u00e4nen P, Sallinen K, M\u00e4kinen M et al (2003) Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 80:954\u2013965. https:\/\/doi.org\/10.1016\/s0015-0282(03)01007-0","journal-title":"Fertil Steril"},{"key":"6700_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/humrep\/det015","volume":"28","author":"R Homburg","year":"2013","unstructured":"Homburg R, Ray A, Bhide P, Bhide P, Gudi A, Shah A et al (2013) The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 28:1077\u20131083. https:\/\/doi.org\/10.1093\/humrep\/det015","journal-title":"Hum Reprod"},{"key":"6700_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/biolre\/iox087","volume":"97","author":"A Oride","year":"2017","unstructured":"Oride A, Kanasaki H, Mijiddorj T, Sukhbaatar U, Hara T, Tumurbaatar T et al (2017) GLP-1 increases Kiss-1 mRNA expression in kisspeptin-expressing neuronal cells. Biol Reprod 97:240\u2013248. https:\/\/doi.org\/10.1093\/biolre\/iox087","journal-title":"Biol Reprod"},{"key":"6700_CR41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1817\/j.issn.1672-7347.2017.11.010","volume":"42","author":"T Wang","year":"2017","unstructured":"Wang T, Fu H, Chen L, Xu Y (2017) Pregnancy complications among women with polycystic ovary syndrome in China: a meta-analysis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 42:1300\u20131310. https:\/\/doi.org\/10.1817\/j.issn.1672-7347.2017.11.010","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"6700_CR42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/humupd\/dmz019","volume":"25","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE (2019) The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update 25:504\u2013517. https:\/\/doi.org\/10.1093\/humupd\/dmz019","journal-title":"Hum Reprod Update"},{"key":"6700_CR43","doi-asserted-by":"publisher","first-page":"E448","DOI":"10.1210\/jc.2010-0853","volume":"95","author":"E Vanky","year":"2010","unstructured":"Vanky E, Stridsklev S, Heimstad R, Romundsta P, Skog\u00f8y K, Kleggetv eit O, et al (2010) Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 95:E448-455. https:\/\/doi.org\/10.1210\/jc.2010-0853","journal-title":"J Clin Endocrinol Metab"},{"key":"6700_CR44","doi-asserted-by":"publisher","first-page":"576917","DOI":"10.3389\/fphys.2021.576917","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu Y, Niu Y, Wang Y, He Y, Ding Y, Lu Y et al (2021) Optimal candidates to do fresh embryo transfer in those using oral contraceptive pretreatment in IVF cycles. Front Physiol 12:576917. https:\/\/doi.org\/10.3389\/fphys.2021.576917","journal-title":"Front Physiol"},{"key":"6700_CR45","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/09513590.2014.995621","volume":"4","author":"JX Pan","year":"2015","unstructured":"Pan JX, Liu Y, Ke ZH et al (2015) Successive and cyclic oral contraceptive pill pretreatment improves IVF\/ICSI outcomes of PCOS patients and ameliorates hyperandrogenism and antral follicle excess. Gynecol Endocrinol 4:332\u2013336. https:\/\/doi.org\/10.3109\/09513590.2014.995621","journal-title":"Gynecol Endocrinol"},{"key":"6700_CR46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3803\/EnM.2021.958","volume":"2","author":"SH Oguz","year":"2021","unstructured":"Oguz SH, Yildiz BO (2021) An update on contraception in polycystic ovary syndrome. Endocrinol Metabol 2:296\u2013311. https:\/\/doi.org\/10.3803\/EnM.2021.958","journal-title":"Endocrinol Metabol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06700-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T04:08:09Z","timestamp":1664338089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["6700"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06700-3","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in this clinical trial were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. On January 8th, 2016, the study was approved by the Medical Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Approved ethic committee number: 002\/2016). The study was registered at Chinese Clinical Trials Registry (ChiCTR-IIR-16008084) on 13\/3\/2016. The long-term follow-up procedures of this clinical trial was reapproved by the Medical Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Approved ethic committee number: 061\/2018) on July 18th, 2018. The study was reregistered at Chinese Clinical Trials Registry (ChiCTR1900020516).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}